Therapy of PsO in Special Subsets of Patients
Psoriasis is a chronic, inflammatory skin disease that may occur at any age, with a bimodal peak of incidence around the age of 16–20 years of age (early onset) and 57–60 years (late-onset). It is estimated that roughly 70% of patients develop the disease before the age of 40, which coincides with t...
Main Authors: | , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-11-01
|
Series: | Biomedicines |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9059/10/11/2879 |
_version_ | 1797469035066032128 |
---|---|
author | Antonella Di Cesare Federica Ricceri Elia Rosi Maria Thais Fastame Francesca Prignano |
author_facet | Antonella Di Cesare Federica Ricceri Elia Rosi Maria Thais Fastame Francesca Prignano |
author_sort | Antonella Di Cesare |
collection | DOAJ |
description | Psoriasis is a chronic, inflammatory skin disease that may occur at any age, with a bimodal peak of incidence around the age of 16–20 years of age (early onset) and 57–60 years (late-onset). It is estimated that roughly 70% of patients develop the disease before the age of 40, which coincides with the reproductive years. Moreover, psoriasis is a chronic disease, meaning that, with increased life-duration expectancy, the number of patients affected with psoriasis aged over 65 years is going to increase and represent a big therapeutic challenge. Actually, no specific drug recommendation is available, based only on the age of the patients, while therapeutic prescription should take into account that elderly patients have more comorbidities than younger patients, with polypharmacy and an increased risk of drug interactions. Women with psoriasis are more likely to report a worse influence of the disease on their quality of life, and they are more susceptible to the development of depression. Furthermore, pregnancy and lactation represent a major contraindication to several systemic agents, and only a few studies exist providing the safety of certain drugs during these periods of life of a woman, such as certolizumab pegol. In this paper, we discuss systemic therapeutic strategies, including conventional and biological therapies, in a special subset of patients affected with moderate-to-severe psoriasis focusing on elderly patients and on female patients in fertile age, pregnancy, and lactation. |
first_indexed | 2024-03-09T19:15:44Z |
format | Article |
id | doaj.art-fc6c782b56d94fdc8de556a6a1061427 |
institution | Directory Open Access Journal |
issn | 2227-9059 |
language | English |
last_indexed | 2024-03-09T19:15:44Z |
publishDate | 2022-11-01 |
publisher | MDPI AG |
record_format | Article |
series | Biomedicines |
spelling | doaj.art-fc6c782b56d94fdc8de556a6a10614272023-11-24T03:52:11ZengMDPI AGBiomedicines2227-90592022-11-011011287910.3390/biomedicines10112879Therapy of PsO in Special Subsets of PatientsAntonella Di Cesare0Federica Ricceri1Elia Rosi2Maria Thais Fastame3Francesca Prignano4Department of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, ItalyDepartment of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, ItalyDepartment of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, ItalyDepartment of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, ItalyDepartment of Health Sciences, Section of Dermatology, University of Florence, 50125 Florence, ItalyPsoriasis is a chronic, inflammatory skin disease that may occur at any age, with a bimodal peak of incidence around the age of 16–20 years of age (early onset) and 57–60 years (late-onset). It is estimated that roughly 70% of patients develop the disease before the age of 40, which coincides with the reproductive years. Moreover, psoriasis is a chronic disease, meaning that, with increased life-duration expectancy, the number of patients affected with psoriasis aged over 65 years is going to increase and represent a big therapeutic challenge. Actually, no specific drug recommendation is available, based only on the age of the patients, while therapeutic prescription should take into account that elderly patients have more comorbidities than younger patients, with polypharmacy and an increased risk of drug interactions. Women with psoriasis are more likely to report a worse influence of the disease on their quality of life, and they are more susceptible to the development of depression. Furthermore, pregnancy and lactation represent a major contraindication to several systemic agents, and only a few studies exist providing the safety of certain drugs during these periods of life of a woman, such as certolizumab pegol. In this paper, we discuss systemic therapeutic strategies, including conventional and biological therapies, in a special subset of patients affected with moderate-to-severe psoriasis focusing on elderly patients and on female patients in fertile age, pregnancy, and lactation.https://www.mdpi.com/2227-9059/10/11/2879psoriasistherapyelderlyfertilitylactationpregnancy |
spellingShingle | Antonella Di Cesare Federica Ricceri Elia Rosi Maria Thais Fastame Francesca Prignano Therapy of PsO in Special Subsets of Patients Biomedicines psoriasis therapy elderly fertility lactation pregnancy |
title | Therapy of PsO in Special Subsets of Patients |
title_full | Therapy of PsO in Special Subsets of Patients |
title_fullStr | Therapy of PsO in Special Subsets of Patients |
title_full_unstemmed | Therapy of PsO in Special Subsets of Patients |
title_short | Therapy of PsO in Special Subsets of Patients |
title_sort | therapy of pso in special subsets of patients |
topic | psoriasis therapy elderly fertility lactation pregnancy |
url | https://www.mdpi.com/2227-9059/10/11/2879 |
work_keys_str_mv | AT antonelladicesare therapyofpsoinspecialsubsetsofpatients AT federicaricceri therapyofpsoinspecialsubsetsofpatients AT eliarosi therapyofpsoinspecialsubsetsofpatients AT mariathaisfastame therapyofpsoinspecialsubsetsofpatients AT francescaprignano therapyofpsoinspecialsubsetsofpatients |